濮阳东方看妇科评价高(濮阳东方看男科病价格偏低) (今日更新中)

The U.S. Census Bureau says only a tiny percentage of records are affected by data irregularities that are putting in jeopardy a year-end deadline for turning in numbers used for divvying up congressional seats. However, released internal documents show the "high complexity" problems could push the release to February 2021. The Census Bureau told a congressional committee Thursday that the anomalies are being resolved as quickly as possible. House Democrats however say documents they obtained from Census sources, despite Trump administration stonewalling, show hundreds of thousands of records are affected.Fixing the irregularities could mean missing a Dec. 31 deadline for the Census Bureau to turn reapportionment numbers in to Congress. The internal Census documents shared by House Democrats show the data issues, which include several "high complexity" problems, could delay the once-a-decade report until February. Although the documents do not specify the extent of the larger issues, they do say incorrect handling of the issues could skew the count smaller or larger in some areas. They also say the Census Bureau estimates they need an additional 20 days for data processing. The bureau says the timeline remains in flux.The Census Bureau issued a statement asserting that "these kinds of anomalies and issues are expected and are similar to the Census Bureau's experience in prior decennial censuses." The Census Bureau Director acknowledged the issues in mid-November, more details and the delayed timeline are coming out now. The timeline is getting attention because it may or may not be after President Donald Trump leaves office on January 20. Trump has expressed interest in excluding unauthorized immigrants from the Census count. There have been challenges in court and questions about whether this could legally be done, and also whether it physically can be done by coming up with a reliable number to exclude. Three lower courts have blocked the directive from Trump saying it violates federal law that says the census should could the "whole number of persons" in each state. The Supreme Court just this week heard arguments in the case. They have not issued their ruling yet. 2215

The White House announced Friday that President Donald Trump intends to appoint Mehmet Oz, better known as Dr. Oz, to his council on sport, fitness and nutrition.Oz is well-known as a host of an eponymous television show on health and medical issues and, before that, for appearances on "The Oprah Winfey Show." But he has become a lightning rod for controversy for featuring what critics say is unscientific advice on his show.In 2015, a group of doctors criticized him harshly, saying he manifested "an egregious lack of integrity" in his TV and promotional work and called his faculty position at Columbia University unacceptable.Oz defended himself in a written statement at the time, saying, "I bring the public information that will help them on their path to be their best selves. We provide multiple points of view, including mine which is offered without conflict of interest."The-CNN-Wire 906

The Trump administration asked the Supreme Court on Monday to put on hold a federal appeals court ruling from last week that narrowed the scope of the travel ban as it applies to a certain class of refugees.In a brief filed with the Supreme Court, Justice Department lawyers said that a three-judge panel from the 9th US Circuit Court of Appeals was wrong to exempt those refugees who have a contractual commitment from resettlement organizations.In a one-sentence order issued Monday afternoon, Justice Anthony Kennedy -- who has jurisdiction over the 9th circuit -- granted the government a temporary stay until Tuesday in order to give the challengers time to respond to the government's petition.The travel ban bars people from Iran, Libya, Somalia, Sudan, Syria and Yemen from entering the US.Last week, the lower court narrowed the scope of the travel ban for extended family members such as grandparents and refugees.In his filing, acting Solicitor General Jeff Wall said DOJ was only asking for a stay for the lower court ruling as it applies to the refugees. Wall said the administration has already been allowing in close family members, but allowing in the refugees would "upend the status quo and do far greater harm to the national interest."The issue of the scope of the ban has been playing out in the lower courts, but the Supreme Court is set to hear the larger issues concerning the merits of the case on October 11. 1442

The US Food and Drug Administration expanded?the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure.New to the list are some valsartan products manufactured by Hetero Labs Ltd. in India, which are labeled as Camber Pharmaceuticals Inc. Test results show that some of the products may be tainted.The FDA announced a valsartan recall in July after lab tests revealed that some drugs could have been tainted with a substance linked to higher risk of cancer. The drug had been recalled in 22 other countries. The expanded recall includes some drugs that contain valsartan and hydrochlorothisazide. Not all of the drugs containing valsartan were affected.N-nitrosodimethylamine or NDMA, the impurity the lab tests found, is considered a?possible carcinogen by the US Environmental Protection Agency. It is an organic chemical that has been used to make liquid rocket fuel, and it can be unintentionally introduced through certain chemical reactions. It's a byproduct of the manufacturing of some pesticides and fish processing.The medicines that are now a part of this expanded list?in the recall are tablets sold by AvKare, A-S Medication Solutions LLC, Bryant Ranch Prepack Inc, Camber Pharmaceuticals, Inc. H J Harkins Company, Northwind Pharmaceuticals, NuCare Pharmaceuticals Inc., Prinston Pharmaceutical Inc. (labeled as Solco Healthcare LLC), Proficient Rx LP, Remedy Repack, Teva Pharmaceuticals (labeled as Major Pharmaceuticals), Teva Pharmaceuticals USA (labeled as Actavis).The FDA also published a list of valsartan products that are not currently recalled. Only the drugs suspected of being tainted with NDMA are on the recall list. If you are taking a valsartan drug, look for the company name on your prescription bottle. If the information isn't on the label, you can call your pharmacy for those details.The recalled medicine is linked to a manufacturer in China. The substances were supplied by Zhejiang Huahai Pharmaceuticals, based in Linhai, in eastern China, which said it notified authorities as soon as it identified the impurity."We published our recall notice at midday on July 13 in China and overseas, and published the US market recall notice on July 14 Beijing time ... all the drug materials for the Chinese market were recalled by July 23," the company said in a statement to the Shanghai stock exchange last month.The FDA said on its website that it's working with drug manufacturers "to ensure future valsartan active pharmaceutical ingredients are not at risk."If you are worried that your drug could be on the recall list, talk with your doctor or pharmacist before changing any routine with your medicine. Because not all valsartan drugs are involved in the recall, they might be able to switch you to a version of the drug made by another company.If you know your drug is on the recall list, the FDA suggests you continue taking it until your doctor or pharmacist provides a replacement.To get a sense of what taking a tainted drug could mean, FDA scientists estimated that if 8,000 people took the highest dose of valsartan (320 milligrams) from the recalled batches every day for four years, there may be one additional case of cancer."The key with this is, patients should not stop taking their medication abruptly, that definitely can be harmful," Dr. Mary Ann Bauman, a representative for the American Heart Association, said in July. "You don't want to jump to any conclusions on your own about this medication, or any medication for that matter. Definitely talk with your doctor first." 3690

The roaring American economy will probably sink into a recession before President Trump stands for re-election in 2020.At least that's the view of Ray Dalio, the billionaire investor who predicted the 2008 financial crisis."The probability of a recession prior to the next presidential election would be relatively high, 70% or something like that," Dalio said on Wednesday evening during an appearance at the Harvard Kennedy School's Institute of Politics.  471

来源：资阳报